|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
2005-2-24
|
|
pubmed:databankReference |
|
|
pubmed:abstractText |
CD4(+) regulatory T (Treg) cells play an important role in the maintenance of immunological self-tolerance by suppressing immune responses against autoimmune diseases and cancer. Yet very little is known about the natural antigenic ligands that preferentially activate CD4(+) Treg cells. Here we report the establishment of tumor-specific CD4(+) Treg cell clones from tumor-infiltrating lymphocytes (TILs) of cancer patients, and the identification of an Ag recognized by Treg cells (ARTC1) gene encoding a peptide ligand recognized by tumor-specific TIL164 CD4(+) Treg cells. The mutations in a gene encoding an ARTC1 in 164mel tumor cells resulted in the translation of a gene product containing the peptide ligand recognized by CD4(+) Treg cells. ARTC1 peptide-activated CD4(+) Treg cells suppress the physiological function (proliferation and IL-2 secretion) of melanoma-reactive T cells. Furthermore, 164mel tumor cells, but not tumor lysates pulsed on B cells, were capable of activating TIL164 CD4(+) Treg cells. These results suggest that tumor cells may uniquely present an array of peptide ligands that preferentially recruit and activate CD4(+) Treg cells in sites where tumor-specific self-peptide is expressed, leading to the induction of local and tumor-specific immune suppression.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, Neoplasm,
http://linkedlifedata.com/resource/pubmed/chemical/DNA, Complementary,
http://linkedlifedata.com/resource/pubmed/chemical/Epitopes, T-Lymphocyte,
http://linkedlifedata.com/resource/pubmed/chemical/Growth Inhibitors,
http://linkedlifedata.com/resource/pubmed/chemical/Interleukin-2,
http://linkedlifedata.com/resource/pubmed/chemical/Ligands,
http://linkedlifedata.com/resource/pubmed/chemical/Peptides,
http://linkedlifedata.com/resource/pubmed/chemical/adenocarcinoma antigen recognized...
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
0022-1767
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
174
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2661-70
|
|
pubmed:dateRevised |
2007-11-14
|
|
pubmed:meshHeading |
pubmed-meshheading:15728473-Amino Acid Sequence,
pubmed-meshheading:15728473-Antigen Presentation,
pubmed-meshheading:15728473-Antigens, Neoplasm,
pubmed-meshheading:15728473-Base Sequence,
pubmed-meshheading:15728473-Cell Culture Techniques,
pubmed-meshheading:15728473-Cell Line, Transformed,
pubmed-meshheading:15728473-Clone Cells,
pubmed-meshheading:15728473-DNA, Complementary,
pubmed-meshheading:15728473-Epitopes, T-Lymphocyte,
pubmed-meshheading:15728473-Growth Inhibitors,
pubmed-meshheading:15728473-Humans,
pubmed-meshheading:15728473-Immunophenotyping,
pubmed-meshheading:15728473-Interleukin-2,
pubmed-meshheading:15728473-Ligands,
pubmed-meshheading:15728473-Lymphocyte Activation,
pubmed-meshheading:15728473-Lymphocytes, Tumor-Infiltrating,
pubmed-meshheading:15728473-Melanoma,
pubmed-meshheading:15728473-Molecular Sequence Data,
pubmed-meshheading:15728473-Mutation,
pubmed-meshheading:15728473-Peptides,
pubmed-meshheading:15728473-T-Lymphocytes, Regulatory,
pubmed-meshheading:15728473-Tumor Cells, Cultured
|
|
pubmed:year |
2005
|
|
pubmed:articleTitle |
Recognition of a new ARTC1 peptide ligand uniquely expressed in tumor cells by antigen-specific CD4+ regulatory T cells.
|
|
pubmed:affiliation |
Center for Cell and Gene Therapy and Department of Immunology, Baylor College of Medicine, Houston, TX 77030, USA.
|
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.
|
